Scinai Immunotherapeutics annual stock-based compensation
2017
2020
2021
2022
2023
2024
2025
Scinai Immunotherapeutics Stock-Based Compensation Growth & History (SCNI)
Scinai Immunotherapeutics's stock-based compensation was $303,000 for fiscal 2025.
View full Scinai Immunotherapeutics company overviewScinai Immunotherapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $303,000 | −$379,000 | −55.57% |
| 2024 | 2024-12-31 | $682,000 | −$457,000 | −40.12% |
| 2023 | 2023-12-31 | $1.1M | −$463,000 | −28.90% |
| 2022 | 2022-12-31 | $1.6M | −$1.3M | −44.04% |
| 2021 | 2021-12-31 | $2.9M | −$83,000 | −2.82% |
| 2020 | 2020-12-31 | $2.9M | — | — |
| 2017 | 2017-12-31 | $150,000 | — | — |
Scinai Immunotherapeutics quarterly stock-based compensation
Q1.22
Q2.22
Q1.23
Q2.23
Q4.24
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $58,000 | −$212,000 | −78.52% |
| Q1 2026 | 2026-03-31 | $70,000 | $70,000 | — |
| Q2 2025 | 2025-06-30 | $270,000 | — | — |
| Q1 2025 | 2025-03-31 | $0 | — | — |
| Q4 2024 | 2024-12-31 | $204,000 | — | — |
| Q2 2023 | 2023-06-30 | $200,000 | −$185,000 | −48.05% |
| Q1 2023 | 2023-03-31 | $252,000 | −$233,000 | −48.04% |
| Q2 2022 | 2022-06-30 | $385,000 | — | — |
| Q1 2022 | 2022-03-31 | $485,000 | — | — |
Scinai Immunotherapeutics stock-based compensation trends
Over the last five fiscal years, Scinai Immunotherapeutics's stock-based compensation decreased from $2.9M to $303,000, a change of −$2.6M. The latest reported quarter, Q2 2026, shows $58,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Scinai Immunotherapeutics source filings ↗